background
increas
level
monocyt
angiotensinconvert
enzym
ace
found
haemodialysi
hd
patient
may
directli
particip
pathogenesi
atherosclerosi
demonstr
recent
uremia
trigger
develop
highli
proatherogen
monocyt
via
angiotensin
ii
angii
depend
mechan
oppos
action
angiidegrad
remain
larg
unknown
examin
statu
ace
relat
receptor
circul
leukocyt
hd
notdialyz
ckd
healthi
individu
furthermor
test
possibl
impact
monocyt
ace
atherogenesi
behaviour
cell
condit
mimick
chronic
renal
failur
method
express
ace
masr
investig
circul
leukocyt
hd
year
ckd
stage
year
patient
healthi
control
subject
year
isol
healthi
monocyt
treat
normal
urem
serum
analys
ace
mcsf
endotheli
adhes
test
aceoverexpress
monocyt
treat
captopril
losartan
monocyt
subject
transmigr
adhes
assay
investig
mcsf
express
result
ace
mrna
level
significantli
increas
hd
ckd
stage
leukocyt
correspondingli
downregul
angii
well
ma
receptor
express
upregul
cell
healthi
monocyt
background
increas
level
monocyt
angiotensinconvert
enzym
ace
found
haemodialysi
hd
patient
may
directli
particip
pathogenesi
atherosclerosi
demonstr
recent
uremia
trigger
develop
highli
proatherogen
monocyt
via
angiotensin
ii
angii
depend
mechan
oppos
action
angiidegrad
remain
larg
unknown
examin
statu
ace
relat
receptor
circul
leukocyt
hd
notdialyz
ckd
healthi
individu
furthermor
test
possibl
impact
monocyt
ace
atherogenesi
behaviour
cell
condit
mimick
chronic
renal
failur
method
express
ace
masr
investig
circul
leukocyt
hd
year
ckd
stage
year
patient
healthi
control
subject
year
isol
healthi
monocyt
treat
normal
urem
serum
analys
ace
mcsf
endotheli
adhes
test
aceoverexpress
monocyt
treat
captopril
losartan
monocyt
subject
transmigr
adhes
assay
investig
mcsf
express
result
ace
mrna
level
significantli
increas
hd
ckd
stage
leukocyt
correspondingli
downregul
angii
well
ma
receptor
express
upregul
cell
healthi
monocyt
precondit
urem
serum
reflect
expression
regul
ma
angii
receptor
observ
hd
ckd
stage
leukocyt
overexpress
monocyt
ace
dramat
decreas
level
induc
proatherogen
phenotyp
partli
revers
angiimodifi
treatment
lead
increas
overexpress
monocyt
led
reduc
endotheli
adhes
transmigr
downregul
adhesionrel
molecul
conclus
hd
notdialyz
ckd
stage
patient
show
enhanc
ace
decreas
express
monocyt
constel
render
cell
endotheli
adhes
like
support
develop
atherosclerosi
keyword
atherosclerosi
ckd
monocyt
uremia
overactiv
reninangiotensin
system
ra
observ
pathophysiolog
condit
chronic
kidney
diseas
ckd
common
factor
lead
cardiovascular
complic
frequent
observ
chronic
inflamm
ckd
patient
mainten
intermitt
haemodialysi
hd
play
crucial
role
develop
progress
atherosclerosi
relat
cardiovascular
event
myocardi
infarct
stroke
pharmacolog
blockad
ra
exert
benefici
effect
patient
slow
prevent
cardioren
diseas
progress
suggest
involv
noncanon
ra
factor
action
classic
ra
mediat
angiotensinconvert
enzym
ace
gener
angiotensin
ii
angii
potent
vasoconstrictor
main
ra
effector
proinflammatori
proprolif
action
angii
may
counteract
recent
describ
degrad
angii
potent
vasodil
ace
abundantli
express
human
cardiac
pulmonari
renal
tissu
organ
liver
placenta
central
nervou
system
ace
also
express
surfac
monocyt
macrophag
smooth
muscl
cell
recent
demonstr
elev
level
monocyt
ace
hd
patient
associ
increas
mortal
cardiovascular
morbid
may
also
particip
initi
step
atherosclerosi
recent
investig
reveal
urem
condit
upregul
express
monocyt
ace
drive
monocyt
proatherogen
differenti
via
angiidepend
mechan
mous
model
demonstr
ace
defici
bone
marrowderiv
cell
decreas
hypercholesterolemiainduc
atherosclerosi
macrophag
mice
promot
atherosclerosi
increas
express
releas
inflammatori
cytokin
elev
adhes
cell
endotheli
cell
convers
adenovirusmedi
overexpress
atherogen
anim
model
abl
decreas
proatherosclerot
action
improv
endotheli
homeostasi
decreas
monocyt
adhes
studi
investig
express
pattern
ace
relat
receptor
circul
leukocyt
obtain
hd
ckd
stage
patient
healthi
control
np
furthermor
examin
regul
primari
human
monocyt
cell
urem
condit
leukocyt
rna
serum
isol
primari
human
monocyt
blood
sampl
rna
serum
isol
obtain
chronic
hd
patient
treat
dialysi
ward
univers
clinic
hall
patient
dialysi
healthi
volunt
hd
patient
treat
thrice
weekli
averag
h
target
ktv
standard
bicarbon
hd
ultrapur
water
revers
osmosi
steril
filter
use
highflux
polynephron
membran
nipro
europ
hd
blood
sampl
obtain
prior
regular
hd
session
dialysi
access
hd
patient
year
age
free
acut
infecti
complic
immunosuppress
medic
hd
patient
divid
group
take
angiotensin
receptor
blocker
arb
n
ace
inhibitor
acei
n
without
angiotensinmodifi
medic
n
patient
treat
depart
intern
medicin
univers
clinic
hall
classifi
accord
gfr
np
normal
renal
function
determin
serum
creatinin
take
medic
hd
patient
np
characterist
present
tabl
blood
sampl
leukocyt
rna
isol
drawn
vacuett
safeti
blood
collect
set
greiner
bioon
tempu
blood
rna
tube
life
technolog
total
rna
isol
tempu
spin
rna
isol
kit
accord
manufactur
instruct
life
technolog
monocyt
vitro
experi
isol
three
healthi
volunt
pan
monocyt
isol
kit
miltenyi
use
automac
cell
separ
miltenyi
accord
manufactur
instruct
studi
approv
ethic
committe
martin
luther
univers
faculti
medicin
patient
person
involv
studi
gave
written
inform
consent
studi
perform
accord
rule
declar
helsinki
cell
cultur
treatment
primari
human
monocyt
cell
note
per
well
primari
human
monocyt
treat
pool
normal
ns
hd
sera
h
rpmi
medium
without
fc
pool
hd
sera
obtain
chronic
hd
patient
n
age
rang
year
male
femal
without
angiotensinmodifi
medic
treat
dialysi
ward
univers
clinic
hall
pool
urem
sera
isol
three
patient
dialysi
male
year
age
take
angiotensinmodifi
medic
ns
obtain
healthi
volunt
n
age
rang
year
male
femal
treatment
perform
hydrophob
sixwel
plate
greiner
bio
one
standard
humidifi
incub
c
co
total
rna
human
primari
monocyt
isol
zr
rna
miniprep
kit
zymo
research
accord
manufactur
instruct
aceangii
receptor
inhibit
studi
perform
captopril
acei
nm
santa
cruz
biotechnolog
losartan
angiotensin
ii
type
receptor
antagonist
mm
santa
cruz
biotechnolog
control
monocyt
stabli
overexpress
ace
accord
trojanowicz
et
al
captopril
losartan
concentr
correspond
observ
clinic
condit
human
umbil
vein
endotheli
cell
huvec
cultur
medium
supplement
low
serum
growth
supplement
lsg
gibco
cultur
transfect
primari
monocyt
full
code
sequenc
ace
describ
previous
gener
cell
stabli
overexpress
human
cell
transfect
plasmid
carri
full
code
sequenc
receiv
gift
dr
e
lazartigu
control
cell
receiv
empti
plasmid
transfect
method
describ
previous
microscop
investig
live
cell
phase
contrast
modu
perform
lightfluoresc
microscop
biozero
keyenc
total
rna
isol
use
zr
rna
miniprep
kit
zymo
research
accord
manufactur
instruct
depend
experi
mg
total
rna
use
templat
firststrand
cdna
synthesi
high
capac
cdna
revers
transcript
kit
accord
manufactur
instruct
life
technolog
sampl
store
c
amplif
ace
masr
actb
ribosom
protein
perform
taqman
gene
express
assay
life
technolog
faststart
univers
probe
master
mix
roch
stepon
plu
system
actb
use
normal
target
mrna
express
thermal
cycl
condit
follow
hold
min
c
follow
cycl
c
c
amplif
macrophag
colonystimul
factor
mcsf
angiotensin
ii
type
ii
receptor
intercellular
adhes
molecul
vascular
cell
adhes
molecul
monocyt
chemotact
cc
motif
ligand
perform
sequenc
condit
accord
trojanowicz
et
al
data
evalu
perform
dataassist
softwar
life
technolog
dot
line
within
quantit
pcr
qpcr
graph
repres
express
target
transcript
refer
sampl
set
evalu
purpos
total
protein
lyse
ripa
buffer
supplement
proteas
inhibitor
western
blot
perform
mg
total
protein
separ
sdspage
blot
onto
polyvinyliden
difluorid
membran
membran
block
h
bsa
dissolv
trisbuff
salin
tween
buffer
thereaft
primari
santa
cruz
biotechnolog
bactin
cell
signal
antisera
block
buffer
appli
overnight
c
h
room
temperatur
respect
final
secondari
antirabbit
hrpconjug
antibodi
santa
cruz
biotechnolog
employ
protein
band
visual
ecl
kit
pierc
analys
bactin
express
measur
area
specif
protein
band
repres
pixel
intens
perform
alphaview
softwar
proteinsimpl
area
control
band
set
compar
area
band
normal
purpos
intens
bactin
band
subtract
intens
band
adhes
monocyt
endotheli
huvec
monolay
transmigr
assay
perform
accord
trojanowicz
et
al
experi
repeat
least
three
time
data
present
mean
sd
median
interquartil
rang
distribut
quantit
variabl
test
use
dagostinopearson
omnibu
test
depend
data
distribut
statist
signific
calcul
wilcoxonmannwhitney
ttest
linear
regress
model
appli
adjust
age
gender
regard
leukocyt
mrna
express
supplementari
data
tabl
p
consid
statist
signific
graphpad
prism
spss
softwar
use
statist
analys
express
decreas
masr
ace
angii
receptor
type
upregul
hd
leukocyt
order
investig
express
pattern
masr
receptor
angii
receptor
circul
cell
patient
chronic
renal
failur
subject
leukocyt
obtain
np
hd
patient
qpcr
specif
ace
masr
probe
primer
demonstr
figur
express
hd
group
significantli
decreas
compar
healthi
control
contrast
level
masr
notabl
increas
hd
group
figur
furthermor
express
ace
significantli
upregul
hd
patient
figur
angii
receptor
show
significantli
elev
express
hd
patient
compar
np
express
differ
figur
e
investig
leukocyt
balanc
ace
demonstr
express
ratio
significantli
elev
hd
group
compar
np
group
figur
express
ace
differ
hd
patient
take
arb
n
acei
n
treat
angiotensinmodifi
medic
n
figur
c
arb
therapi
hd
patient
reduc
elev
express
toward
level
np
howev
differ
signific
compar
patient
treat
angiotensinmodifi
medic
figur
e
investig
diabet
nondiabet
hd
patient
reveal
differ
express
ace
angii
receptor
masr
within
examin
group
supplementari
data
tabl
demonstr
previous
urem
milieu
lead
upregul
express
monocyt
ace
increas
transmigr
endotheli
adhes
compar
treatment
ns
ace
express
pattern
observ
leukocyt
obtain
hd
patient
influenc
serum
incub
express
well
angiotensin
receptor
test
primari
human
monocyt
incub
h
hd
serum
lead
significantli
reduc
express
elev
level
masr
figur
e
compar
ns
thu
urem
milieu
induc
complet
express
pattern
normal
monocyt
found
cell
isol
dialysi
patient
order
unravel
whether
hd
may
affect
observ
chang
patient
leukocyt
investig
addit
express
target
transcript
patient
dialysi
demonstr
figur
c
express
ace
patient
similar
observ
hd
patient
differ
significantli
np
express
masr
patient
significantli
upregul
compar
np
figur
e
addit
level
masr
significantli
higher
hd
patient
figur
investig
leukocyt
balanc
ace
demonstr
express
ratio
significantli
elev
group
compar
np
figur
uremiamedi
upregul
ace
express
correl
increas
adhes
transmigr
monocyt
report
previou
studi
overexpress
ace
plasmidmedi
transfect
also
lead
mark
decreas
express
primari
monocyt
cell
figur
effect
revers
least
part
acei
captopril
lesser
degre
arb
losartan
figur
indic
local
format
angii
monocyt
ace
import
effect
express
like
block
losartan
play
role
regul
addit
effect
overexpress
ace
monocyt
also
lead
significantli
elev
cellular
adhes
figur
g
upregul
express
mcsf
molecul
involv
cellcel
interact
particularli
monocyteendothelium
figur
c
demonstr
figur
c
captopril
well
losartan
lead
significantli
decreas
express
mcsf
aceoverexpress
cell
effect
captopril
stronger
losartan
overexpress
lead
reduc
endotheli
adhes
transmigr
monocyt
overexpress
smaller
correspond
control
figur
function
cell
reveal
decreas
endotheli
adhes
figur
g
lower
transmigr
rate
diminish
express
figur
e
overexpress
lead
inhibit
adhesionrel
molecul
well
reduc
express
angiotensin
receptor
figur
studi
show
circul
leukocyt
obtain
hd
ckd
patient
express
less
ace
detect
notic
stronger
compar
leukocyt
healthi
individu
ace
produc
vasoconstrict
angii
degrad
angii
vasodil
alter
relat
ace
may
contribut
ubiquit
arteri
hypertens
dialysi
patient
addit
receptor
angii
receptor
masr
upregul
knowledg
first
report
describ
elev
express
masr
dialysi
patient
particular
phenotyp
induc
vitro
incub
monocyt
serum
dialysi
patient
kovarik
et
al
show
elev
plasma
level
dialysi
patient
compar
healthi
control
explain
express
pattern
monocyt
thu
sourc
patient
like
previou
report
reveal
receptor
angii
detect
major
leukocyt
subset
highest
express
granulocyt
monocyt
correl
pathophysiolog
condit
agreement
data
highlevel
express
shown
ckd
patient
furthermor
individu
high
risk
vascular
event
hyperlipidem
patient
express
circul
leukocyt
notic
elev
compar
healthi
lowrisk
control
group
pharmacolog
intervent
either
ra
blocker
statin
led
decreas
express
interf
angii
exert
antiinflammatori
action
patient
recent
chon
et
al
studi
nondialyz
ckd
patient
found
despit
relev
antihypertens
effect
angiotensin
blockad
consist
affect
leukocyt
express
author
postul
factor
involv
uremia
domin
modul
leukocyt
express
patient
contrast
find
therapi
angii
receptor
blocker
hd
patient
led
degre
reduct
leukocyt
express
experiment
overexpress
ace
monocyt
lead
downregul
effect
like
transmit
via
format
angii
ligat
sinc
inhibit
ace
inhibit
part
angiotensin
receptor
blockad
interact
via
demonstr
previous
express
pattern
found
dialysi
patient
associ
enhanc
express
adhes
molecul
well
activ
cytokin
mcsf
transfect
experi
overexpress
ace
induc
molecul
angiotensin
receptor
blocker
losartan
revert
induct
contrast
overexpress
opposit
effect
downregul
adhesionpromot
molecul
find
agreement
earlier
data
suggest
ace
counterregulatori
mechan
within
kidney
heart
astrocyt
also
within
circul
leukocyt
result
allow
specul
urem
milieu
induc
specif
dysregul
express
respons
format
proinflammatori
adhes
monocyt
phenotyp
fit
well
earlier
data
show
high
express
ace
monocyt
dialysi
patient
associ
subclin
atherosclerosi
cardiovascular
mortal
comparison
healthi
popul
significantli
lower
leukocyt
masr
upregul
level
seem
urem
environ
especi
urem
toxin
may
affect
proper
function
local
axi
counterregulatori
mechan
urem
toxin
abl
induc
vascular
damag
ckd
also
may
induc
compon
ra
shimizu
et
al
demonstr
indoxyl
sulphat
one
repres
urem
toxin
upregul
angiotensinogen
agt
express
proxim
tubular
cell
sun
et
al
report
pcresol
sulphat
upregul
addit
elev
agt
express
reninangiotensinaldosteron
system
compon
renin
studi
vanhold
et
al
pletinck
et
al
show
clearli
proinflammatori
effect
trigger
proteinbound
urem
toxin
contribut
vascular
damag
renal
diseas
progress
stimul
crosstalk
leukocyt
vessel
wall
data
rule
addit
particip
system
ra
particularli
sinc
kovarik
et
al
demonstr
elev
level
hd
plasma
may
strongli
upregul
leukocyt
masr
also
worth
note
human
macrophag
react
inflammatori
stimuli
lp
increas
masr
transcript
hand
report
oral
administr
ckd
rat
led
decreas
level
masr
proxim
tubular
cell
contrari
express
compar
increas
masr
urem
leukocyt
could
explain
differ
role
axi
mesangi
tubular
cell
within
kidney
cell
circul
leukocyt
recent
emerg
evid
microrna
may
trigger
silenc
distinct
transcript
caus
develop
andor
progress
renal
diseas
abl
bind
regul
mrna
effect
urem
milieu
express
particular
microrna
must
taken
consider
well
establish
immunolog
mechan
inflamm
strongli
contribut
pathogenesi
atherosclerosi
particularli
suggest
accumul
leukocyt
monocytederiv
macrophag
atherosclerot
lesion
system
chronic
inflamm
commonli
observ
dialysi
patient
one
main
factor
associ
plaqueform
atherosclerosi
compon
local
angiotensin
system
may
interact
system
ra
believ
exert
impact
clinic
outcom
least
atherosclerosi
transcript
data
confirm
function
experi
overexpress
ace
monocyt
lead
phenotyp
decreas
upregul
angiotensin
receptor
cell
show
dramat
augment
endotheli
adhes
transmigr
found
monocyt
overexpress
reveal
significantli
decreas
transmigratori
adhes
properti
also
diminish
level
angii
receptor
import
antiatherogen
antihypertens
action
local
angiotensin
system
reflect
studi
perform
anephr
patient
suggest
patient
system
blood
pressur
mainten
regul
local
tissueor
cellspecif
fashion
independ
system
ra
given
anephr
patient
individu
remain
renal
function
suffer
progress
atherosclerosi
system
local
ra
may
proatherogen
patient
similar
extent
conclus
demonstr
urem
condit
promot
overactiv
monocyt
ace
inhibit
thu
contribut
enhanc
endotheli
adhes
transmigr
may
elucid
import
mechan
contribut
progress
atherosclerosi
patient
chronic
renal
failur
supplementari
data
avail
onlin
http
ndtoxfordjournalsorg
author
declar
compet
interest
grate
manuela
hajri
beat
heinz
excel
technic
assist
